NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state over time, but clinical studies of markers predicting the awakening potential of DTCs are lacking. Recently, experiments have shown that NR2F1 (COUP-TF1) plays a key role in dormancy signaling. We analyzed the NR2F1 expression in DTCs by double immunofluorescence (DIF) staining of extra cytospins prepared from 114 BM samples from 86 selected DTC-positive breast cancer patients. Samples collected at two or more time points were available for 24 patients. Fifteen samples were also analyzed for the proliferation marker Ki67. Of the patients with detectable DTCs by DIF, 27% had ≥ 50% NR2F1 high DTCs, chosen a priori as the cut-off for “dormant profile” classification. All patients with systemic relapse within 12 months after BM aspiration carried ≤ 1% NR2F1 high DTCs, including patients who transitioned from having NR2F1 high -expressing DTCs in previous BM samples. Of the patients with serial samples, half of those with no relapse at follow-up had ≥ 50% NR2F1 high DTCs in the last BM aspiration analyzed. Among the 18 relapse-free patients at the time of the last DTC-positive BM aspiration with no subsequent BM analysis performed, distant disease-free intervals were favorable for patients carrying ≥ 50% NR2F1 high DTCs compared with those with predominantly NR2F1 low DTCs ( p = 0.007, log-rank). No survival difference was observed by classification according to Ki67-expressing DTCs ( p = 0.520). Our study translates findings from basic biological analysis of DTC dormancy to the clinical situation and supports further clinical studies of NR2F1 as a marker of dormancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791
Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H. G., Schewe, D. M., & Aguirre-Ghiso, J. A. (2013) · Nature Cell Biology · doi:10.1038/ncb2861 · Cited by 503
Self-citationVitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy
Cabezas-Wallscheid, N., Buettner, F., Sommerkamp, P., Klimmeck, D., Ladel, L., Thalheimer, F. B., Pastor-Flores, D., Roma, L. P., Renders, S., Zeisberger, P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.018 · Cited by 454
Cited by
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β2
Nobre, A. R., Risson, E., Singh, D. K., Di Martino, J. S., Cheung, J. F., Wang, J., Johnson, J., Russnes, H. G., Bravo-Cordero, J. J., Birbrair, A., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00179-8 · Cited by 159
Self-citationTumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P. (2019) · Cancers · doi:10.3390/cancers11081207 · Cited by 111
“In this respect, epigenetic upregulation of orphan nuclear receptor NR2F1 is detected in DTCs from the breast [131], and prostate cancer patients harboring lifelong dormant disease and in experimental latency models of head and neck squamous cell carcinoma (HNSCC).”
BackgroundThe origins of cancer cell dormancy
Morales-Valencia, J., & David, G. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101914 · Cited by 25
Metadata
- Authors
- Borgen, E., Rypdal, M. C., Sosa, M. S., Renolen, A., Schlichting, E., Lønning, P. E., Synnestvedt, M., Aguirre-Ghiso, J. A., & Naume, B.
- Venue
- Breast Cancer Research
- Published
- 2018-10-16
- Volume
- 20
- Issue
- 1
- Pages
- 120-120
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2898001343
- Cited by
- 114
- References
- 3
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. https://app.cochat.ai/papers/10.1186/s13058-018-1049-0
- The paper
- Borgen, E., Rypdal, M. C., Sosa, M. S., Renolen, A., Schlichting, E., Lønning, P. E., Synnestvedt, M., Aguirre-Ghiso, J. A., & Naume, B. (2018). NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Research. https://doi.org/10.1186/s13058-018-1049-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.